CytoSorbents Achieves Compliance with Nasdaq's Minimum Bid Price Requirement

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

CytoSorbents Corporation, listed on the Nasdaq under the ticker CTSO, is making significant strides in the medical innovation field by complying with the stock market's minimum bid price requirement of $1.00 per share. This development was announced on September 22, 2026, following a solid trading performance that saw the company's shares consistently close at or above the required threshold for ten consecutive trading sessions.

Dr. Phillip Chan, CEO of CytoSorbents, expressed satisfaction with this turnaround, highlighting it as a pivotal step towards reinforcing shareholder confidence and enhancing the organization's market visibility. CytoSorbents is now focused on fulfilling additional Nasdaq Capital Market listing requirements, particularly concerning the minimum Market Value of Listed Securities, which must be addressed by December 28, 2026.

This news comes at a crucial time for CytoSorbents, which has established itself as a leader in treatments for severe health conditions prevalent in intensive care and cardiac surgery settings. Their commitment to developing advanced blood purification technologies has played a vital role in their market standing.

Focus on Core Business Objectives

The company’s primary product, CytoSorb, utilizes proprietary polymer beads designed for blood purification. By removing toxic substances from patients' blood, they address life-threatening conditions that healthcare providers face in critical situations. The versatility of these treatments is notable, being applicable in instances of severe biological crises, such as sepsis, trauma, and organ failure.

CytoSorbents is not only working towards maintaining compliance with Nasdaq regulations but is also intensively focused on various business goals. These include driving sales of CytoSorb, achieving operational cash flow breakeven in the latter half of the year, and progressing its investigational product, DrugSorb-ATR, towards FDA approval. This system is designed to reduce perioperative bleeding risks in patients undergoing high-risk surgeries, empowered through innovative blood-thinning drug removal technologies.

With significant efforts directed toward compliance and product innovation, CytoSorbents aims to position itself for sustainable growth and ensure long-term shareholder value. The company holds several FDA Breakthrough Device Designations for its existing and developing products, emphasizing its commitment to enhancing patient care in critical health scenarios.

Global Distribution and Future Prospects

Having made strides in the European market and currently expanding its reach into other regions, CytoSorbents has distributed over 300,000 devices across more than 70 countries. Their strong presence in international markets underscores the demand for cutting-edge treatment technologies, particularly as healthcare systems increasingly adopt advanced solutions for critical illness management.

In addition to treating serious health complications, the CytoSorb technology is expanding its utility into other medical areas. This includes removing blood thinners during and after surgical procedures and detoxifying blood in liver failure cases. Their growing portfolio of patented products illustrates the company's ongoing dedication to research and innovation.

As CytoSorbents progresses with its objectives, the future remains bright, with expectations of strengthening market performance, regulatory success for new product segments, and continued enhancement of healthcare outcomes through its advanced technologies. The company asks stakeholders to remain informed about its journey and is dedicated to transparency about its growth and compliance strategies moving forward.

For more information on CytoSorbents Corporation and its pioneering blood purification systems, please visit their official website or follow them on social media platforms.